In this Review, we discuss important aspects of CAR T cell therapy in autoimmune disease, including considerations relating to patient selection, safety, efficacy and medical management. These considerations are based on the early experiences of CAR T cell therapy in autoimmune diseases, and as the...
Chimeric antigen receptor (CAR)-T cell therapy has achieved remarkable success in the treatment of hematological malignancies. Based on the immunomodulatory capability of CAR-T cells, efforts have turned toward exploring their potential in treating autoimmune diseases. Bibliometric analysis of 210 records...
The capacity of CD19CAR-T therapy to achieve tissue clearance of autoreactive B-cells is an attractive prospect for patients with autoimmune conditions in whom mAb therapy fails. From leukaemia/lymphoma experience CAR-T therapy is highly effective in patients when prior B-cell targeting mAb therapy...
[1]Schett G, Mackensen A, Mougiakakos D. CAR T-cell therapy in autoimmune diseases. Lancet. 2023 Nov 25;402(10416):2034-2044. doi: 10.1016/S0140-6736(23)01126-1. Epub 2023 Sep 22. PMID: 37748491. [2]Müller ...
CAR T-cell therapy in autoimmune diseases. Lancet. 2023 Nov 25;402(10416):2034-2044. doi: 10.1016/S0140-6736(23)01126-1. Epub 2023 Sep 22. PMID: 37748491. [22] Pecher AC, Hensen L, Klein R, et al. CD19-Targeting CAR T Cells for Myositis and Interstitial Lung Disease Associated ...
Roddie, C. et al. Obecabtagene autoleucel in adults with B-cell acute lymphoblastic leukemia.N. Engl. J. Med.391, 2219–2230 (2024). ArticleCASPubMedGoogle Scholar Wang, M. et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma.N. Engl. J. Med.382, 133...
他们的综述文章于 2024 年 4 月 12 日发表在Chinese Medical Journal期刊上,论文标题为“Dawn of CAR-T cell therapy in autoimmune diseases”。 田教授在解释他们的研究工作背后的动机时说,“CAR-T细胞疗法在根除病理B细胞和实现持续缓解方面的胜利,推动了科学家们探索它在自身免疫性疾病中的潜在应用,如系统性...
T cells obtained from the patient's blood, and infusion back to the patients. CAR-T cell immunotherapy has led to a significant improvement in the remission rates of hematological cancers. CAR-T cell therapy presently limited to hematological cancers, there are ongoing efforts to develop ...
Levine, B. L. et al. Unanswered questions following reports of secondary malignancies after CAR-T cell therapy. Nature Medicine volume 30, pages338–341 (2024) Deswal, P. CAR-T therapies and cancer risk: No easy answers for the FDA. Pharmaceut...
CAR T therapy extends its reach to autoimmune diseases. Cell 185, 4471–4473 (2022). Article CAS PubMed Google Scholar Müller, F. et al. CD19-targeted CAR T cells in refractory antisynthetase syndrome. Lancet 401, 815–818 (2023). A case report of a patient with antisynthetase ...